IDH mutations: Genotype-phenotype correlation and prognostic impact

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wang, Xiao Wei ^a,b,c   Ciccarino, Pietro ^a,b,c   Rossetto, Marta ^a,b,c   Boisselier, Blandine ^a,b,c   Marie, Yannick ^d   Desestret, Virginie ^a,b,c,e   Gleize, Vincent ^a,b,c   Mokhtari, Karima ^a,b,c,e   Sanson, Marc ^a,b,c,e   Labussière, Marianne ^a,b,e  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 2; PROTEIN P53; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CHROMOSOME 1P; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIA; OVERALL SURVIVAL; ADOLESCENT; AGED; CHROMOSOME 1; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901267070     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/540236     Document Type: Article

References (29)

1. Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K., Burger P. C., Jouvet A., Scheithauer B. W., Kleihues P., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007 114 97 109 (Pubitemid 47103521)
2. Figarella-Branger D., Bouvier C., Histological classification of human gliomas: state of art and controversies. Bulletin du Cancer 2005 92 4 301 309 2-s2.0-18344390291 (Pubitemid 40755339)
3. Coons S. W., Johnson P. C., Scheithauer B. W., Yates A. J., Pearl D. K., Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997 79 1381 1393 (Pubitemid 27143246)
4. Kros J. M., Grading of gliomas: the road from eminence to evidence. Journal of Neuropathology and Experimental Neurology 2011 70 2 101 109 2-s2.0-79251599407 10.1097/NEN.0b013e31820681aa
5. van den Bent M. J., Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathologica 2010 120 3 297 304 2-s2.0-77956227086 10.1007/s00401-010-0725-7
6. Parsons D. W., Jones S., Zhang X., Lin J. C.-H., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I.-M., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A. Jr., Hartigan J., Smith D. R., Strausberg R. L., Marie S. K. N., Shinjo S. M. O., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W., An integrated genomic analysis of human glioblastoma multiforme. Science 2008 321 5897 1807 1812 2-s2.0-52949127312 10.1126/science.1164382
7. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A., Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica 2008 116 6 597 602 2-s2.0-56749156414 10.1007/s00401-008-0455-2
8. Bleeker F. E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W. P., Frattini M., Molinari F., Knowles M., Cerrato A., Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S., Marchetti A., Bardelli A., IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors. Human Mutation 2009 30 1 7 11 2-s2.0-58349111311 10.1002/humu.20937
9. Ohgaki H., Kleihues P., Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science 2009 100 12 2235 2241 2-s2.0-70449711757 10.1111/j.1349-7006.2009.01308.x
10. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., Hallani S. E., Boisselier B., Mokhtari K., Hoang-Xuan K., Delattre J.-Y., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology 2009 27 25 4150 4154 2-s2.0-70249097408 10.1200/JCO.2009.21.9832
11. Yan H., Parsons D. W., Jin G., McLendon R., Rasheed B. A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G. J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K. W., Velculescu V. E., Vogelstein B., Bigner D. D., IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine 2009 360 8 765 773 2-s2.0-60849115270 10.1056/NEJMoa0808710
12. Idbaih A., Marie Y., Lucchesi C., Pierron G., Manié E., Raynal V., Mosseri V., Hoang-Xuan K., Kujas M., Brito I., Mokhtari K., Sanson M., Barillot E., Aurias A., Delattre J.-Y., Delattre O., BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. International Journal of Cancer 2008 122 8 1778 1786 2-s2.0-40349089779 10.1002/ijc.23270 (Pubitemid 351413424)
13. Boisselier B., Marie Y., Labussière M., Ciccarino P., Desestret V., Wang X., Capelle L., Delattre J.-Y., Sanson M., COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Human Mutation 2010 31 12 1360 1365 2-s2.0-78649585883 10.1002/humu.21365
14. Everhard S., Kaloshi G., Crinière E., Benouaich-Amiel A., Lejeune J., Marie Y., Sanson M., Kujas M., Mokhtari K., Hoang-Xuan K., Delattre J.-Y., Thiller J., MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Annals of Neurology 2006 60 6 740 743 2-s2.0-33846009775 10.1002/ana.21044 (Pubitemid 46048490)
15. Idbaih A., Boisselier B., Sanson M., Crinière E., Liva S., Marie Y., Carpentier C., Paris S., Laigle-Donadey F., Mokhtari K., Kujas M., Hoang-Xuan K., Delattre O., Delattre J.-Y., Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. Cancer Genetics and Cytogenetics 2007 176 2 121 126 2-s2.0-34447552655 10.1016/j.cancergencyto.2007.04.012 (Pubitemid 47081202)
16. Labussière M., Idbaih A., Wang X.-W., Marie Y., Boisselier B., Falet C., Paris S., Laffaire J., Carpentier C., Crinière E., Ducray F., El Hallani S., Mokhtari K., Hoang-Xuan K., Delattre J.-Y., Sanson M., All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010 74 23 1886 1890 2-s2.0-77953351926 10.1212/WNL.0b013e3181e1cf3a
17. Labussiere M., Sanson M., Idbaih A., Delattre J.-Y., IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 2010 15 2 196 199 2-s2.0-77649148205 10.1634/theoncologist.2009-0218
18. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H., IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. American Journal of Pathology 2009 174 4 1149 1153 2-s2.0-65349150503 10.2353/ajpath.2009.080958
19. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J. W. M., Wesseling P., Reifenberger G., von Deimling A., Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica 2009 118 4 469 474 2-s2.0-69949114447 10.1007/s00401-009-0561- 9
20. Ichimura K., Pearson D. M., Kocialkowski S., Bäcklund L. M., Chan R., Jones D. T. W., Collins V. P., IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology 2009 11 4 341 347 2-s2.0-68349116524 10.1215/15228517-2009-025
21. + T cells. European Journal of Immunology 2006 36 8 2076 2084 2-s2.0-33747385010 10.1002/eji.200535163 (Pubitemid 44251753)
22. Metellus P., Coulibaly B., Colin C., De Paula A. M., Vasiljevic A., Taieb D., Barlier A., Boisselier B., Mokhtari K., Wang X. W., Loundou A., Chapon F., Pineau S., Ouafik L., Chinot O., Figarella-Branger D., Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathologica 2010 120 6 719 729 2-s2.0-78651067051 10.1007/s00401-010-0777-8
23. Nobusawa S., Watanabe T., Kleihues P., Ohgaki H., IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clinical Cancer Research 2009 15 19 6002 6007 2-s2.0-70349653793 10.1158/1078-0432.CCR- 09-0715
24. Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J. P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J. C., Heese O., Krex D., Nikkhah G., Pietsch T., Wiestler O., Reifenberger G., Von Deimling A., Loeffler M., Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of Clinical Oncology 2009 27 34 5743 5750 2-s2.0-73349103157 10.1200/JCO.2009.23.0805
25. Dubbink H. J., Taal W., van Marion R., Kros J. M., Van Heuvel I., Bromberg J. E., Zonnenberg B. A., Zonnenberg C. B. L., Postma T. J., Gijtenbeek J. M. M., Boogerd W., Groenendijk F. H., Smitt P. A. E. S., Dinjens W. N. M., Van Den Bent M. J., IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009 73 21 1792 1795 2-s2.0-73349108806 10.1212/WNL.0b013e3181c34ace
26. Gravendeel L. A. M., Kloosterhof N. K., Bralten L. B. C., Van Marion R., Dubbink H. J., Dinjens W., Bleeker F. E., Hoogenraad C. C., Michiels E., Kros J. M., Van Den Bent M., Smitt P. A. E. S., French P. J., Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Human Mutation 2010 31 3 E1186 E1199 2-s2.0-77149152775 10.1002/humu.21201
27. Cairncross G., Wang M., Shaw E., Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology 2013 31 337 343
28. van den Bent M. J., Brandes A. A., Taphoorn M. J., Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of Clinical Oncology 2013 31 344 350
29. Cairncross J. G., Wang M., Jenkins R. B., Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology 2014 10.1200/JCO.2013.49.3726